Latest revenue
$301.7M
as of 2026-03-31
Latest net income
$-112.1M
as of 2026-03-31
Net margin
-37.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $15.77B
- Enterprise value
- $15.77B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $121.01
- 52-wk low
- $37.73
- Beta
- —
- Shares out
- 132.6M
5-year trend
What this company does
Item 1. Business Overview We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For patients with advanced-stage cancer, we offer the Guardant360 Liquid test, formerly known as the Guardant360 LDT test, and the Guardant360 CDx test, the first…
AI summary unavailable — showing raw filing excerpt
Generated from GH's filing dated 2026-02-19
Key risks
Item 1A. Risk Factors Risk Factors Our operations and financial results are subject to various risks and uncertainties including those described below. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes. The risks and uncertainties described below are not the only ones we face. If any of the following risks or others not specified below materialize, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline. Risks…
AI summary unavailable — showing raw filing excerpt
Generated from GH's filing dated 2026-02-19
Profitability
Operating margin
-44.5%
25.8%Net margin
-42.4%
28.2%Return on equity
419.2%
34.1%Return on assets
-20.7%
29.6%Leverage
Debt / equity
-21.28×
82.8%Debt / assets
104.9%
4.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $301.7M | +48.3% | $-112.1M | -17.8% | -37.2% |
Q4 2025 2025-12-31 | $281.3M | +39.4% | $-128.5M | -15.8% | -45.7% |
Q3 2025 2025-09-30 | $265.2M | +38.5% | $-92.7M | +13.9% | -35.0% |
Q2 2025 2025-06-30 | $232.1M | +30.9% | $-99.9M | +2.7% | -43.0% |
Q1 2025 2025-03-31 | $203.5M | +20.8% | $-95.2M | +17.2% | -46.8% |
Q4 2024 2024-12-31 | $201.8M | — | $-111.0M | — | -55.0% |
Q3 2024 2024-09-30 | $191.5M | +33.9% | $-107.8M | -25.1% | -56.3% |
Q2 2024 2024-06-30 | $177.2M | +29.2% | $-102.6M | -41.0% | -57.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on GH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$81.3M
Net activity
−$81.3M
Distinct insiders
13
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GH
Institutional value
$5.94B
Total shares held
66.9M
Distinct holders
301
-20 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 11.6M | $1.07B | +236.0K (+2.1%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.8M | $539.3M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 5.6M | $519.5M | — | New |
| 4 | Invesco Ltd. | 4.9M | $456.9M | -369.5K (-7.0%) | Trimmed |
| 5 | BAILLIE GIFFORD & CO | 3.9M | $356.5M | — | New |
| 6 | Capital International Investors | 3.5M | $321.6M | -47.3K (-1.3%) | Trimmed |
| 7 | FRANKLIN RESOURCES INC | 3.4M | $318.5M | +86.6K (+2.6%) | Added |
| 8 | FEDERATED HERMES, INC. | 1.9M | $174.4M | -144.0K (-7.1%) | Trimmed |
| 9 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.6M | $150.0M | -292.1K (-15.2%) | Trimmed |
| 10 | UBS Group AG | 1.4M | $129.9M | — | New |
| 11 | Bank of New York Mellon Corp | 1.4M | $128.5M | +25.0K (+1.8%) | Added |
| 12 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1.4M | $125.9M | +823.3K (+152.7%) | Added |
| 13 | Temasek Holdings (Private) Ltd | 985.6K | $91.0M | -58.5K (-5.6%) | Trimmed |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 951.1K | $87.9M | — | New |
| 15 | VANGUARD FIDUCIARY TRUST CO | 889.9K | $82.2M | — | New |
| 16 | EMERALD ADVISERS, LLC | 841.9K | $77.8M | -19.9K (-2.3%) | Trimmed |
| 17 | Artisan Partners Limited Partnership | 814.6K | $75.2M | +524.2K (+180.5%) | Added |
| 18 | Erste Asset Management GmbH | 815.9K | $70.3M | -230.0K (-22.0%) | Trimmed |
| 19 | Allspring Global Investments Holdings, LLC | 608.8K | $55.5M | — | New |
| 20 | Walleye Capital LLC | 583.9K | $53.9M | +329.6K (+129.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once GH's latest filing finishes processing.